Malaysia
Search
Sign In
Gastroenterology
Top Medical News
A specific carbohydrate diet (SCD) and a modified SCD (MSCD) demonstrate inconsistent effectiveness for the improvement of symptoms in inflammatory bowel disease (IBD), with some patients benefitting and others not, reports a study.
Patients with colorectal cancer (CRC) have a substantially altered gut microbiome, characterized by changes in bacterial composition, according to a recent Singapore study. Of note, these alterations persist even after surgery.
One-week vonoprazan-based triple therapy is well tolerated and has comparable efficacy as the 2-week proton pump inhibitor (PPI)-based triple therapy for first-line Helicobacter pylori eradication, according to a study.
Treatment with endoscopic submucosal dissection (ESD) for rectal tumours extending to the dentate line (RTDLs) remains safe and feasible despite its poorer outcomes relative to non-RTDLs if appropriate lesions are handled by experienced operators, suggests a study.
Undergoing appendectomy may put patients at risk of developing subsequent microscopic colitis, although the risk increase appears to be modest, as shown in a study.
Use of medication is markedly different among older patients with inflammatory bowel disease (IBD), with more aminosalicylate monotherapy and less antitumour necrosis factor monotherapy than younger patients, according to a US study.
In what has been dubbed as ‘a small but mighty study’ at ASCO 2022, a phase II trial spearheaded by investigators from Memorial Sloan Kettering Cancer Center in New York, US heralded the remarkable efficacy and safety of the monoclonal antibody dostarlimab for the treatment of locally advanced mismatch repair-deficient (dMMR) rectal cancer.
Special Reports
SALOFALK – Mesalazine 1.5 g PR granules
Overall survival (OS) is currently the primary criteria in assessing the efficacy of a cancer treatment. Dr Raghav Sundar, a consultant medical oncologist at the National University Hospital, Singapore, details the crucial role played by tumour response in evaluating treatment efficacy, with a focus on the multiple kinase inhibitor lenvatinib in the treatment of hepatocellular carcinoma (HCC).
Advancements in genomics has paved the way for better classifications of colorectal cancers (CRC) and the use of precision therapy.
DUKORAL – Inactivated Vibrio cholerae O1 serogroup & recombinant cholera toxin B subunit (WC/rCTB) vaccine (oral) – AJ Biologics
Conference Reports
Maintenance therapy with the anti-IL-23p19 antibody mirikizumab boosts clinical benefits in moderate-to-severe ulcerative colitis (UC) in the phase III LUCENT-2 trial, improving bowel urgency that is not only disruptive but likewise embarrassing for patients.
Despite no other indication or proven clinical benefit, proton pump inhibitors (PPIs) are frequently inappropriately used to treat lower gastrointestinal bleeding (LGIB), according to a study presented at the recently concluded 2022 Digestive Disease Week (DDW 2022).
The investigational microbiota-based live biotherapeutic RBX2660 is safe and averts repeat episodes of Clostridioides difficile infection (CDI) across patient populations with comorbid conditions, as shown in a study presented at Digestive Disease Week (DDW) 2022.
Treatment with tenapanor improves symptoms in patients with irritable bowel syndrome with constipation (IBS-C) as early as week 1 of treatment, according to two phase III studies presented at DDW 2022.
Antibiotic use appears to be harmful for older adults, with a recent study showing that regardless of class, the drugs raise the risk of developing inflammatory bowel disease (IBD).
Individuals with nonalcoholic fatty liver disease (NAFLD) – despite having a lean body or healthy BMI – are at an elevated risk for peripheral vascular disease, stroke, and cardiovascular disease (CVD), a finding that surprises gastroenterologists and researchers at DDW 2022.
Use of statins results in reduced all-cause mortality in nearly 30,000 veterans with colorectal cancer (CRC), results of a study have shown.
